CJC-1295 (No DAC) / Ipamorelin Blend

CJC-1295 (No DAC) + Ipamorelin

Overview:
CJC-1295 (No DAC) + Ipamorelin is a dual-peptide research blend designed for studies focused on pulsatile signaling models, endocrine pathway interactions, and peptide-driven cellular communication. This combination allows researchers to examine how multiple signaling peptides interact within controlled laboratory environments, providing a structured model for investigating coordinated receptor activity and temporal signaling dynamics.

Scientific Background:
CJC-1295 (No DAC) is a modified growth hormone-releasing hormone (GHRH) analog commonly studied for its role in receptor binding and signaling cascades associated with endogenous hormone release patterns. Without the Drug Affinity Complex (DAC), it is frequently utilized in research models focused on shorter-duration activity and pulsatile signaling behavior.

Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist studied for its interaction with growth hormone secretagogue pathways. In controlled laboratory settings, it is analyzed for receptor specificity, signaling efficiency, and pathway selectivity.

When combined, CJC-1295 (No DAC) and Ipamorelin provide a complementary research model for examining dual-pathway peptide signaling, receptor interaction dynamics, and coordinated cellular communication processes.

Specifications:

• Composition: CJC-1295 (No DAC) 10mg / Ipamorelin 10mg (20mg total)
• Purity: ≥99%
• Form: Lyophilized powder blend
• Storage: -20°C
• Solubility: Sterile or bacteriostatic water

Disclaimer:
For laboratory research use only. Not for human consumption, medical use, or veterinary use.

Bourbon Peptides — Research Grade Purity.